ArticlePloS one2026
Development of predictive models for the prognosis of triple-negative breast cancer using multiple transcriptomic analyses.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) and constitutes approximately 15-20% of all BC cases. This subtype has the most aggressive behavior and the worst prognosis. Numerous studies have been conducted over the past several decades to address the lack of clinically available treatment options. In particular, potential markers targeting effective treatment options have been actively studied. However, these efforts were hindered by the complex mechanisms of TNBC, and no study has demonstrated a model with a predictive performance exceeding 0.85. This study developed TNBC prognosis predictive models with a predictive performance exceeding 0.94. Applying the nine selected markers to five independent datasets demonstrated their potential as TNBC-specific prognostic markers. Most of these genes (including GPR61, PZP, IGFL1, and AHCTF1) are associated with overall survival (OS) in patients with TNBC. Based on these results, these nine selected genes may serve as prognostic markers for OS in patients with TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.